1. Home
  2. VVOS vs LIXT Comparison

VVOS vs LIXT Comparison

Compare VVOS & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vivos Therapeutics Inc.

VVOS

Vivos Therapeutics Inc.

HOLD

Current Price

$2.05

Market Cap

19.4M

Sector

Health Care

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$4.06

Market Cap

20.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VVOS
LIXT
Founded
2016
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.4M
20.5M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
VVOS
LIXT
Price
$2.05
$4.06
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$6.75
N/A
AVG Volume (30 Days)
116.0K
85.0K
Earning Date
11-19-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,317,000.00
N/A
Revenue This Year
$19.45
N/A
Revenue Next Year
$70.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.76
N/A
52 Week Low
$1.98
$0.64
52 Week High
$7.95
$6.26

Technical Indicators

Market Signals
Indicator
VVOS
LIXT
Relative Strength Index (RSI) 33.84 42.81
Support Level $2.03 $3.53
Resistance Level $2.33 $4.80
Average True Range (ATR) 0.16 0.45
MACD 0.00 -0.01
Stochastic Oscillator 4.35 35.07

Price Performance

Historical Comparison
VVOS
LIXT

About VVOS Vivos Therapeutics Inc.

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: